Showing results (1471-1480 of 1,708) with videos related to
Sort By:
Pageof 171
The American Journal of Medicine|March 17, 2022
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES TrialRenato D Lopes, Patrícia O Guimarães, Gregory G Schwartz, et al.Diabetes Care|December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 StudyAvivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.Journal of the American College of Cardiology|September 9, 2017
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54Marc P Bonaca, Robert F Storey, Pierre Theroux, et al.Diabetologia|February 21, 2021
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitusMichelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, et al.Journal of the American Heart Association|February 18, 2026
Timeliness of Care for Transferred and Directly Admitted Patients With Anticoagulation-Associated Intracerebral HemorrhageRegina Royan, Jeffrey L Saver, Nicole Solomon, et al.Med (New York, N.Y.)|March 29, 2024
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trialEhab Bakbak, Aishwarya Krishnaraj, Deepak L Bhatt, et al.European Heart Journal. Cardiovascular Pharmacotherapy|April 7, 2022
Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCIDavide Cao, Julie A Swain, Samantha Sartori, et al.Circulation. Cardiovascular Interventions|June 1, 2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trialRobert C Welsh, Sunil V Rao, Uwe Zeymer, et al.Journal of the American College of Cardiology|September 21, 2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus AspirinJohn W Eikelboom, Jacqueline J Bosch, Stuart J Connolly, et al.Circulation|August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical TrialSubodh Verma, C David Mazer, Andrew T Yan, et al.Pageof 171